Boston Scientific has reported a net income of $324m, or $0.22 per diluted share for the second quarter ended 30 June 2024, a 24% rise compared to $261m, or $0.18 per diluted share, for the respective quarter in 2023.
The medical device company’s net income for the second quarter of 2024 (Q2 2024) declined by 34% compared to $495m, or $0.33 per diluted share, for the first quarter of 2024 (Q1 2024).
Boston Scientific reported net sales of $4.12bn for Q2 2024, a 14.5% increase compared to $3.59bn for the same quarter in 2023, and a 7% decline compared to $3.85bn for Q1 2024.
The medical device company reported operating expenses of $2.33bn for Q2 2024, a 15% rise compared to $2.02bn for the same period the previous year.
The company reported income before tax of $420 for Q2 2024, a 1.4% decline compared to $426 for the corresponding quarter last year.
Boston Scientific chairman and CEO Mike Mahoney said: “We delivered a quarter marked by exceptional performance, reflecting our global team’s relentless pursuit of innovation that is supported by strong clinical evidence and investments aligned with our strategy of category leadership.
“We remain excited about our plans for the future, and I am incredibly grateful for the commitment and winning spirit of our employees around the world.”
Boston Scientific has reported a net income of $815m, or $0.55 per diluted share, for the six months ended 30 June 2024, a 40% rise compared to $584m, or $0.39 per diluted share, for the respective period the previous year.
The medical device maker reported net sales of $7.97bn for the first half of 2024 (H1 2024), a 17.6% increase compared to $6.98bn for the same period in 2023.
The company has reported operating expenses of $4.3bn for H1 2024, a 12.5% rise compared to $3.82bn for the respective period in the previous year.
Boston Scientific reported an operating income of $1.19bn for H1 2024, a 12% increase compared to $1.06bn for the same period in 2023.
Recently, Boston Scientific has launched the AGENT Drug-Coated Balloon in the US, and received approval in China, to treat in-stent restenosis in patients with coronary artery disease.
Also, the medical device company has agreed to acquire Silk Road Medical, which develops an advanced platform to prevent stroke in patients with carotid artery disease, for $1.16bn.
